Skip to main content

Table 1 Baseline characteristics of the study population

From: A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Variables, n (%) Alectinib (n = 43) Ceritinib (n = 22) p-value
Age, median (range), year 62 (48 ~ 66) 57 (54 ~ 74) 0.501
Sex
 male 19 (44.2) 9 (40.9) 1.000
 female 24 (55.8) 13 (59.1)  
Smoking history
 Smoker/ex-smoker 8 (18.6) 2 (9.1) 0.520
 Nonsmoker 35 (81.4) 20 (90.9)  
ECOG PS
 0 /1 40 (93.0) 20 (90.9) 1.000
 2/ 3 3 (7.0) 2 (9.1)  
Histology
 Adenocarcinoma 43 (100.0) 22 (100.0) 1.000
Brain metastasis
 Yes 13 (37.2) 11 (50.0) 0.426
 No 30 (62.8) 11 (50.0)  
Cause of crizotinib treatment failure
 Resistance 26 (60.5) 14 (63.6) 1.000
 Intolerance 17 (39.5) 8 (36.4)  
Prior chemotherapy
 Yes 12 (27.9) 14 (63.6) 0.012
 No 31 (72.1) 8 (36.4)  
  1. ECOG PS Eastern Cooperative Oncology Group performance status
\